-
-
-
-
-
-
-
Ocular Therapeutix™ to Present at the H.C. Wainwright 23rd Annual Global Investment Conference
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Poised to Recover as Dextenza Grows 50% Sequentially - Piper Sandler
-
-
-
-
-
-
-
Ocular Therapeutix™ Reports First Quarter 2021 Financial Results and Business Update
-
-
-
-
-
-
-
Ocular Therapeutix™ Announces FDA Acceptance of Supplemental New Drug Application for DEXTENZA® (dexamethasone ophthalmic insert) for the Treatment of Ocular Itching Associated with Allergic Conjun
-
-
-
-
-
-
-
Ocular Therapeutix™ Promotes Michael Goldstein, MD, MBA, to President, Ophthalmology and Appoints Rabia Gurses Ozden, MD as Senior Vice President, Clinical Development
-
-
-
-
-
-
-
Ocular Therapeutix (OCUL) Announces FDA Approval of DEXTENZA for Treatment of Ocular Pain
-
-
-
-
-
-
-
Ocular Therapeutix™ to Present at the 2018 Cantor Global Healthcare Conference
-
12,349 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All